NASDAQ:BLTE Belite Bio Q2 2025 Earnings Report $67.99 +1.68 (+2.53%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$67.65 -0.34 (-0.50%) As of 08/6/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Belite Bio EPS ResultsActual EPSN/AConsensus EPS -$0.42Beat/MissN/AOne Year Ago EPSN/ABelite Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABelite Bio Announcement DetailsQuarterQ2 2025Date8/11/2025TimeAfter Market ClosesConference Call DateMonday, August 11, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Belite Bio Earnings HeadlinesA Look At The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE)July 27, 2025 | finance.yahoo.comBelite Bio to Participate in the BTIG Virtual Biotechnology ConferenceJuly 25, 2025 | tmcnet.comCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? Depending on when you watch this new training, crypto income could be hitting your account as early as tonight! | Awesomely, LLC (Ad)Belite Bio Inc ADR News (BLTE) - Investing.comJuly 23, 2025 | investing.comBelite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic AtrophyJuly 2, 2025 | globenewswire.comBelite Bio stock holds $80 target on FDA breakthrough nodMay 23, 2025 | investing.comSee More Belite Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Belite Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Belite Bio and other key companies, straight to your email. Email Address About Belite BioBelite Bio (NASDAQ:BLTE), Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.View Belite Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 LifelinePalantir Stock Soars After Blowout Earnings ReportVertical Aerospace's New Deal and Earnings De-Risk ProductionAmazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT? Upcoming Earnings Gilead Sciences (8/7/2025)Monster Beverage (8/7/2025)Constellation Energy (8/7/2025)Becton, Dickinson and Company (8/7/2025)Brookfield (8/7/2025)Canadian Natural Resources (8/7/2025)ConocoPhillips (8/7/2025)Diageo (8/7/2025)EOG Resources (8/7/2025)Flutter Entertainment (8/7/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
